Lupin gets USFDA nod to market generic Droxidopa capsules

Droxidopa capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness, lightheadedness

49
Medicine Capsule
Picture: Pixabay

Global pharma major Lupin Limited has received approval for its droxidopa capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd.

The product will be manufactured at Lupin’s facility in Nagpur, India.

Droxidopa capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH).

These indications are caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta- hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Droxidopa capsules had estimated annual sales of US$352 million in the US, according to IQVIA MAT December 2020.


Also read:

Aurobindo Pharma gets USFDA nod for generic Droxidopa capsules

Zydus Cadila gets USFDA nod for low Blood Pressure drug

Dr Reddy’s Labs launches generic Fluphenazine HCL tablets

Shilpa Medicare gets Import Alert from USFDA


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading

LEAVE A REPLY

Please enter your comment!
Please enter your name here